Theseus Pharmaceuticals Inc (NASDAQ:THRX) Director Carl L. Gordon bought 17,320 shares of the stock in a transaction dated Thursday, January 13th. The shares were acquired at an average price of $9.43 per share, with a total value of $163,327.60. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of THRX stock opened at $11.73 on Friday. The company has a 50 day moving average of $13.52. Theseus Pharmaceuticals Inc has a 52 week low of $8.65 and a 52 week high of $24.54.
Theseus Pharmaceuticals (NASDAQ:THRX) last issued its earnings results on Monday, November 15th. The company reported ($5.16) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($4.93). Equities research analysts predict that Theseus Pharmaceuticals Inc will post -1.72 EPS for the current year.
Theseus Pharmaceuticals Company Profile
Theseus Pharmaceuticals Inc is a biopharmaceutical company. It focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. The company’s principal product candidate includes THE-630. Theseus Pharmaceuticals Inc is based in CAMBRIDGE, Mass.
Featured Story: How Do You Calculate Return on Investment (ROI)?
Receive News & Ratings for Theseus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theseus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.